Acurx Pharmaceuticals (ACXP) Prepaid Assets (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Prepaid Assets came in at $228826.0 in Q1 2026, up 41.62% YoY from $161574.0 in Q1 2025, and up 169.15% on a QoQ basis from $85018.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Prepaid Assets (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Prepaid Assets data on file, last reported at $228826.0 in Q1 2026.
- Quarterly Prepaid Assets rose 41.62% year-over-year to $228826.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $228826.0 (up 41.62% YoY) and the FY2025 annual result came in at $85018.0, down 15.09% from the prior year.
- Prepaid Assets advanced to $228826.0 in Q1 2026, from $85018.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $337807.0 in Q3 2022 to a low of $53522.0 in Q2 2025.
- A 5-year average of $160794.9 and a median of $158201.0 in 2025 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets plunged 68.7% — and 2024, when it surged 87.24%.
- Tracing ACXP's Prepaid Assets over 5 years: stood at $264955.0 in 2022, then slumped by 60.08% to $105776.0 in 2023, then declined by 5.34% to $100123.0 in 2024, then decreased by 15.09% to $85018.0 in 2025, then surged by 169.15% to $228826.0 in 2026.
- The last three Prepaid Assets figures came in at $228826.0 (Q1 2026), $85018.0 (Q4 2025), and $158201.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Acurx Pharmaceuticals | 6.35 Mn | 6.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233,084.00 |
| Mar 31, 2026 | 228,826.00 |
| Dec 31, 2025 | 85,018.00 |
| Sep 30, 2025 | 158,201.00 |
| Jun 30, 2025 | 53,522.00 |
| Mar 31, 2025 | 161,574.00 |
| Dec 31, 2024 | 100,123.00 |
| Sep 30, 2024 | 122,822.00 |
| Jun 30, 2024 | 168,407.00 |
| Mar 31, 2024 | 187,908.00 |
| Dec 31, 2023 | 105,776.00 |
| Sep 30, 2023 | 105,722.00 |
| Jun 30, 2023 | 89,942.00 |
| Mar 31, 2023 | 206,601.00 |
| Dec 31, 2022 | 264,955.00 |
| Sep 30, 2022 | 337,807.00 |
| Jun 30, 2022 | 116,856.00 |
| Mar 31, 2022 | 239,454.00 |
| Dec 31, 2021 | 295,304.00 |
| Sep 30, 2021 | 530,582.00 |